Aptiganel

Aptiganel synthesis

Aptiganel (also known by its chemical name, Aptiganel hydrochloride, and its developmental code name, CNS 1102) is an experimental drug that was investigated for its potential use in the treatment of acute ischemic stroke. Despite initial promise in early-stage clinical trials, its development was ultimately discontinued due to lack of efficacy and safety concerns in later-phase clinical studies.

Development and Mechanism of Action[edit | edit source]

Aptiganel was developed as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. The NMDA receptor is a subtype of the glutamate receptor, which plays a crucial role in the pathophysiology of ischemic stroke. During an ischemic stroke, excessive glutamate release and subsequent overactivation of NMDA receptors lead to calcium influx, neuronal injury, and death. By inhibiting the NMDA receptor, Aptiganel aimed to protect neurons from glutamate-induced excitotoxicity, potentially reducing the extent of brain damage following a stroke.

Clinical Trials[edit | edit source]

Initial phase I and II clinical trials suggested that Aptiganel had a neuroprotective effect in patients with acute ischemic stroke. However, phase III clinical trials failed to demonstrate a significant improvement in neurological outcomes or a reduction in mortality rates among stroke patients treated with the drug. Moreover, the trials revealed significant safety concerns, including adverse effects such as hypotension and hallucinations, which contributed to the decision to halt further development of Aptiganel.

Discontinuation[edit | edit source]

The development of Aptiganel was discontinued in the late 1990s. The failure of Aptiganel, along with several other NMDA receptor antagonists tested for stroke treatment around the same time, led to a reevaluation of the strategy targeting NMDA receptors for neuroprotection in stroke. The challenges faced by Aptiganel and similar compounds underscored the complexity of stroke pathophysiology and the difficulty of translating neuroprotective strategies from preclinical models to effective clinical treatments.

Impact on Stroke Research[edit | edit source]

The study of Aptiganel contributed to a better understanding of the role of NMDA receptors in ischemic brain injury and the challenges associated with targeting these receptors for stroke therapy. It also highlighted the importance of safety and efficacy in the development of neuroprotective drugs. Despite its ultimate failure, the research on Aptiganel paved the way for future investigations into novel therapeutic targets and approaches for the treatment of stroke.